List of Excipients in Branded Drug LIDOCAINE

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Endo USA Inc	LIDOCAINE	lidocaine	0603-1880	CARBOXYMETHYLCELLULOSE SODIUM
Endo USA Inc	LIDOCAINE	lidocaine	0603-1880	DIHYDROXYALUMINUM AMINOACETATE
Endo USA Inc	LIDOCAINE	lidocaine	0603-1880	EDETATE DISODIUM
Endo USA Inc	LIDOCAINE	lidocaine	0603-1880	GELATIN

Generic Drugs Containing LIDOCAINE

Company	Ingredient	NDC	Excipient
Hikma Pharmaceuticals USA Inc	lidocaine hydrochloride	0143-9579	HYDROCHLORIC ACID
Hikma Pharmaceuticals USA Inc	lidocaine hydrochloride	0143-9579	METHYLPARABEN
Hikma Pharmaceuticals USA Inc	lidocaine hydrochloride	0143-9579	SODIUM CHLORIDE
Hikma Pharmaceuticals USA Inc	lidocaine hydrochloride	0143-9579	SODIUM HYDROXIDE

What are the Most Frequently-Used Excipients in LIDOCAINE?

# Of NDCs	Excipient
29	CARBOXYMETHYLCELLULOSE SODIUM
1	CELLULOSE GUM
2	DIETHYLENE GLYCOL MONOETHYL ETHER
30	DIHYDROXYALUMINUM AMINOACETATE

Excipient Strategy and Commercial Opportunities for Lidocaine

Last updated: February 26, 2026

What is the current excipient landscape for lidocaine formulations?

Lidocaine formulations utilize a variety of excipients to optimize stability, solubility, and delivery. Common excipients include:

• Buffer agents: Acetic acid and sodium hydroxide to adjust pH.
• Preservatives: Methylparaben, propylparaben, and benzyl alcohol for multi-dose formulations.
• Solvents: Ethanol and propylene glycol enhance solubility.
• Vasoconstrictors: Epinephrine prolongs anesthetic effects.
• Carriers and stabilizers: Hydroxypropyl cellulose, sodium chloride for isotonicity and stability.

The choice of excipients varies based on the formulation type:

Formulation Type	Typical Excipients
Topical anesthetics	Carbomers, ethanol, preservatives
Injectable anesthetics	Sodium chloride, sodium hydroxide, benzyl alcohol
Transdermal patches	Polyethylene, adhesives, permeation enhancers

How do excipient choices influence the market and development pathways?

Excipient selection impacts regulatory approval, patenting strategies, and patient safety. Regulatory agencies, such as the FDA and EMA, enforce strict limits on certain excipients, especially preservatives and solvents.

• Patents: Novel combinations or concentrations of excipients can be patented, creating exclusivity.
• Formulation stability: Improved excipient systems extend shelf life and reduce manufacturing costs, contributing to competitive advantages.
• Patient safety considerations: Use of preservative-free formulations addresses sensitivities, opening niche markets.

What are the commercial opportunities linked to excipient innovation?

1. Developing preservative-free formulations: Larger demand due to reduced adverse reactions, especially in pediatric and sensitive populations. This area includes preservative-free lidocaine patches and injectables.

2. Novel excipient combinations: Enhanced drug stability and controlled release properties. For example, encapsulation within new polymer matrices could prolong anesthetic effects, enabling longer dosing intervals and reducing administration frequency.

3. Alternative solvents and permeation enhancers: Safer, more effective options can enable transdermal and topical delivery systems, expanding usage beyond current indications.

4. Biocompatible, biodegradable excipients: Meeting regulatory and environmental standards to reduce adverse effects and facilitate global market access.

What are the key patent and regulatory considerations?

• Patent filings often focus on specific excipient combinations, delivery systems, or formulations with unique stability profiles.
• Regulatory approval depends on data demonstrating safety and efficacy related to excipient components; some excipients previously considered safe are now scrutinized for long-term effects.

Who are the main players and what are their strategies?

• Large pharmaceutical companies: Invest in excipient innovation to extend market exclusivity of lidocaine products.
• Specialty excipient manufacturers: Develop new excipients targeting improved stability, safety, and delivery systems.
• Contract development organizations: Support for formulation customization emphasizing excipient selection.

What are the future trends?

• Increased focus on preservative-free and biocompatible formulations.
• Utilization of nanotechnology and liposomal delivery systems involving novel excipients.
• Emphasis on excipient transparency and safer profiles for global approval.

Key Takeaways

• Excipients in lidocaine formulations influence stability, safety, and delivery.
• Innovation in excipient systems can expand market opportunities, especially preservative-free and controlled-release formulations.
• Regulatory constraints shape formulation development, emphasizing safety and efficacy.
• Patent landscape pivots around novel excipient combinations and delivery systems.
• Future growth hinges on biocompatible, biodegradable excipients and advanced delivery technologies.

FAQs

1. Which excipients are most critical for lidocaine topical formulations?

Carbomers, ethanol, and preservatives are essential to ensure stability, permeability, and microbial safety.

2. How does excipient choice affect patentability?

Novel combinations or concentrations that improve stability, efficacy, or safety can be patented, offering exclusivity.

3. Are preservative-free lidocaine formulations commercially available?

Yes, preservative-free patches and injectables are available, targeting sensitive patient populations.

4. What regulatory challenges exist for excipient innovation?

Demonstrating long-term safety and stability of new excipient combinations is essential for approval.

5. What future excipient trends could influence lidocaine product development?

Use of biodegradable, biocompatible excipients and nanocarrier systems are emerging areas.

References

[1] Anderson, J. et al. (2021). "Regulatory considerations for excipients in injectable products." International Journal of Pharmaceutics, 596.
[2] Smith, L. A. (2019). "Advances in transdermal drug delivery systems." Journal of Controlled Release, 315, 45–56.
[3] Zhang, X. et al. (2020). "Patents on pharmaceutical excipients: Trends and strategic developments." Patent Law Journal, 22(4), 201–220.
[4] U.S. Food and Drug Administration. (2022). Inactive Ingredient Database.